DrugPatentWatch Database Preview
Drugs in Development Information for Huperzine-A
Drug Development Status for Huperzine-A: Patents, clinical trial progress, indications
Huperzine-A is an investigational drug.
There have been 10 clinical trials for Huperzine-A.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2016.
The most common disease conditions in clinical trials are Alzheimer Disease, Schizophrenia, and Cognition Disorders. The leading clinical trial sponsors are Shanghai Mental Health Center, National Institute on Aging (NIA), and Baylor College of Medicine.
There are four US patents protecting this investigational drug and twenty-nine international patents.
Summary for Huperzine-A
| US Patents | 4 |
| International Patents | 29 |
| US Patent Applications | 11 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2016-11-01) |
| Vendors | 27 |
Recent Clinical Trials for Huperzine-A
| Title | Sponsor | Phase |
|---|---|---|
| Effects of Hearing Rehabilitative Interventions and Huperzine A on Presbycusis(Δ,kHz, dB,MMSE, AD) | Zhijun Bao | N/A |
| Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging | Shanghai Mental Health Center | Phase 4 |
| Effects of Huperzine A in Treatment of Moderate to Severe TBI | Spaulding Rehabilitation Hospital | Phase 2 |
Clinical Trial Summary for Huperzine-A
Top disease conditions for Huperzine-A
Top clinical trial sponsors for Huperzine-A
US Patents for Huperzine-A
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Huperzine-A | Start Trial | Intermediates useful for the synthesis of huperzine A | Georgetown University (Washington, DC) | Start Trial |
| Huperzine-A | Start Trial | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs | BrainCells Inc (San Diego, CA) | Start Trial |
| Huperzine-A | Start Trial | Combinations containing a 4-acylaminopyridine derivative | BrainCells Inc. (San Diego, CA) | Start Trial |
| Huperzine-A | Start Trial | Huperzine A and its derivatives as analgesic agents | Start Trial | |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Huperzine-A
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Huperzine-A | Australia | 4343501 | 2020-03-08 | Start Trial |
| Huperzine-A | World Intellectual Property Organization (WIPO) | 0166524 | 2020-03-08 | Start Trial |
| Huperzine-A | Australia | 2006282896 | 2025-08-26 | Start Trial |
| Huperzine-A | Canada | 2620333 | 2025-08-26 | Start Trial |
| Huperzine-A | European Patent Office | 1928437 | 2025-08-26 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
